Klotho Research Overview (also known as α-Klotho, Klotho Protein, Klotho-Derived Peptides (KP1, KP6))
A transmembrane anti-aging protein (KL gene) and family of derived peptides (KP1, KP6) under preclinical investigation. Membrane-bound Klotho co-receptors FGF23/FGFR1c to regulate phosphate and vitamin D; soluble Klotho circulates as a hormone suppressing TGF-β, Wnt, NF-κB, and insulin/IGF-1 signaling. KP1 specifically blocks TGF-β/TβR2 to reduce renal fibrosis in mouse models. Klotho deficiency accelerates CKD, vascular calcification, neurodegeneration, and aging; overexpression extends murine lifespan ~20–30%. No human trials have administered exogenous Klotho or KP1; currently studied as a biomarker only. All RUO.
What Is Klotho?
Klotho is a transmembrane anti-aging protein encoded by the KL gene. The human KL gene encodes three distinct protein subfamilies — α-Klotho, β-Klotho, and γ-Klotho — of which α-Klotho is the longevity-associated form of primary research interest. α-Klotho is expressed mainly in the renal distal convoluted tubule, with additional expression in the choroid plexus, parathyroid gland, and sex organs (ovary, placenta, testis). Within α-Klotho, three structural forms are recognized: full-length membrane-bound Klotho, which acts as a co-receptor for FGF23 regulating phosphate excretion and vitamin D metabolism; soluble Klotho (s-Klotho, ~130 kDa), shed from the membrane and circulating as a pleiotropic protective hormone with an estimated plasma half-life of ~7.5 hours; and a secreted splice variant with similar systemic effects.
In peptide research, Klotho appears in two distinct contexts:
- Endogenous Klotho protein and its domains (KL1/KL2) as a therapeutic target and biomarker studied across CKD, cardiovascular disease, neurodegeneration, and aging.
- Klotho-derived peptides — especially KP1, a 30-amino-acid fragment (residues 56–87) designed to block TGF-β/TβR2 signaling — engineered to recapitulate Klotho's anti-fibrotic activity in a smaller, drug-like format.
Mice lacking Klotho develop an accelerated-aging syndrome (arteriosclerosis, osteoporosis, early death); overexpression extends lifespan 20–30%. Low Klotho levels in humans correlate with CKD progression, vascular calcification, cognitive decline, and frailty. No human trials have yet administered exogenous Klotho protein or KP1 — all RUO vendor materials are sold strictly for research use.
Serum α-Klotho Reference Ranges (Healthy Adults)
Circulating soluble α-Klotho declines progressively with age regardless of sex — a trend attributed to physiological aging rather than disease:
| Age Range | Mean Serum Klotho |
|---|
| 18–35 years | ~932 pg/mL |
| 35–55 years | ~797 pg/mL |
| 55–85 years | ~612 pg/mL |
pg = picogram; 1,000 pg = 1 ng. Total circulating s-Klotho body pool is estimated at ~2.5–15 μg, with older individuals at the lower end and younger individuals at the upper end.
Key Benefits (Preclinical & Observational)
- Anti-aging & lifespan extension — Klotho overexpression extends lifespan ~20–30% in mouse models; suppresses insulin/IGF-1 and Wnt pathways to attenuate cellular senescence and preserve stem-cell pools.
- Kidney and anti-fibrotic protection — s-Klotho blocks TGF-β and Wnt/β-catenin to prevent fibroblast activation and chronic fibrosis; KP1 accumulates in injured kidneys and reduces creatinine, BUN, and fibrosis markers in preclinical CKD models.
- Cardiovascular health — reduces vascular calcification, cardiac fibrosis, and endothelial dysfunction; enhances nitric oxide (NO) production to promote vasodilation and improved blood flow; associated with lower cardiovascular event rates in observational human cohorts.
- Neuroprotection & cognition — even a single s-Klotho injection improved cognition in aged mice; the KL-VS variant (higher Klotho expression) confers measurable cognitive advantages across the human lifespan.
- Metabolic regulation — safeguards pancreatic islets, enhances insulin production, and reduces blood glucose; relevant to diabetes and metabolic syndrome models.
- Anti-inflammatory & antioxidant — suppresses NF-κB signaling and upregulates antioxidant defenses, lowering oxidative damage and pro-inflammatory cytokines.
- Mitochondrial biogenesis — upregulates mitochondrial mass and density in high-energy organs (heart, brain, kidney, lung, and skeletal muscle); this systemic energy upgrade underlies many of Klotho's multi-organ protective effects, distinguishing it from mitochondria-targeted peptides like SS-31 or MOTS-c.
- Pulmonary health — circulating α-Klotho protects lung tissue via a pulmonary-renal crosstalk axis; Klotho deficiency (from aging or CKD) markedly increases susceptibility to acute lung injury and chronic pulmonary dysfunction.
- Physical endurance & muscle preservation — Klotho-deficient mice show significantly reduced exercise capacity; higher serum Klotho correlates inversely with low muscle mass (sarcopenia) in middle-aged adults; preclinical data suggest augmented basal metabolic rate and energy expenditure.
Mechanism of Action
FGF23-dependent mineral metabolism: Membrane Klotho forms a complex with FGFR1c, acting as the obligate co-receptor for FGF23 in renal tubular cells. This axis governs phosphate excretion, vitamin D (1,25-OH₂D) activation, and calcium balance — all critical for bone density and vascular health. Circulating s-Klotho additionally acts as a portable FGF23 co-receptor, extending FGF23-dependent mineral regulation to tissues that do not express membrane Klotho.
Soluble Klotho as endocrine hormone: s-Klotho (shed from the membrane) circulates in blood, CSF, and urine and exerts effects independent of FGF23:
- Anti-fibrotic — blocks TGF-β and Wnt/β-catenin, preventing fibroblast activation and ECM deposition in kidney, lung, and heart.
- Anti-inflammatory — suppresses NF-κB; reduces TNF-α, IL-6, and other pro-inflammatory cytokines.
- Antioxidant — upregulates endogenous antioxidant defenses; reduces reactive oxygen species and oxidative damage.
- Ion channel regulation — modulates Ca²⁺, K⁺, and other channels and transporters in renal and vascular tissue.
- Tumor suppressor — attenuates oncogenic signaling in select cancer contexts.
Aging & stem-cell preservation: Klotho suppresses insulin/IGF-1 and Wnt signaling, attenuates telomere shortening, preserves stem-cell pools, and upregulates mitochondrial biogenesis — increasing mitochondrial mass and density in high-energy organs (heart, brain, kidney, lung, and skeletal muscle) to drive its systemic anti-aging and organ-resilience effects.
KP1 mechanism (Klotho-derived peptide 1): KP1 is a 30-residue peptide derived from Klotho's sequence that specifically binds TGF-β receptor 2 (TβR2) with Kd ≈ 1.4 μM, blocking TGF-β/TβR2 engagement. This inhibits downstream Smad2/3 and MAPK activation, repressing fibroblast activation and preventing upregulation of fibronectin and α-SMA. In UUO and ischemia-reperfusion mouse models, IV KP1 preferentially accumulates in injured kidneys, reduces creatinine and BUN, ameliorates fibrosis, and restores endogenous Klotho expression.
Research Indications
CKD & Renal Fibrosis
Klotho deficiency accelerates CKD progression, renal fibrosis, and mineral imbalance. KP1 inhibits TGF-β signaling and fibroblast activation in mouse renal fibrosis models (UUO, ischemia-reperfusion), improving kidney function markers and reducing fibrotic burden. KP6 similarly targets Wnt/β-catenin in diabetic kidney disease models.
Cardiovascular Disease
Klotho reduces vascular calcification, endothelial dysfunction, and cardiac fibrosis in animal models. Human observational studies link lower serum Klotho to higher cardiovascular event rates. Clinical work focuses on Klotho as a biomarker for cardiovascular risk stratification.
Neurodegeneration & Cognition
Circulating Klotho declines with age and correlates with cognitive function. Notably, s-Klotho cannot cross the blood-brain barrier yet still improves cognition — the leading mechanism involves upregulation of endothelial LRP1 (low-density lipoprotein receptor-related protein 1), which enhances clearance of amyloid-β plaques from the brain. In a landmark 2023 Nature study (Dubal et al.), a single s-Klotho injection improved spatial memory in aged non-human primates from 45% to 60% accuracy; effects persisted for two weeks post-injection, and low doses were effective while high doses were not. The KL-VS human genetic variant (higher Klotho expression) confers measurable cognitive advantages across the lifespan. Active research area for Alzheimer's and Parkinson's disease models.
Metabolic Syndrome & Diabetes
Klotho safeguards pancreatic islets, enhances insulin production, and reduces blood glucose. Animal models suggest relevance to type 2 diabetes and metabolic syndrome via attenuated insulin/IGF-1 signaling and improved cellular glucose handling.
Pulmonary Health
α-Klotho is not normally expressed in lung tissue but is critical for pulmonary health through systemic circulation. Klotho deficiency — from aging, CKD, or metabolic disease — reduces the lung's cytoprotective capacity, predisposing to acute lung injury and chronic pulmonary dysfunction. In rodent ischemia-reperfusion models, repletion of circulating α-Klotho alleviates pulmonary complications independent of kidney injury severity. Higher circulating Klotho positively correlates with better pulmonary function in human observational data, reflecting a pulmonary-renal crosstalk axis central to multi-organ aging.
Anti-Aging & Longevity
Klotho overexpression extends murine lifespan 20–30% and improves healthspan markers: delayed CKD progression, reduced cardiovascular events, better cognition, preserved stem-cell pools, and lower senescence burden. Human observational data link higher serum Klotho to lower frailty and better overall outcomes with aging.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Introductory | 10 mcg | Once every 2 weeks | SubQ or IM |
| Intensive Research | 10 mcg | 2–3x per week | SubQ or IM |
Note
No established dose-escalation protocol exists. The 10 mcg starting dose is drawn from researcher community documentation. Objective biomarker tracking (eGFR, FGF23, serum Klotho if measurable) is essential to assess response.
Peptide Interactions
Membrane Klotho + FGFR1c form the receptor complex for FGF23, regulating phosphate excretion and vitamin D metabolism.
KP1 binds TβR2 (Kd ≈ 1.4 μM), preventing TGF-β engagement, blocking Smad2/3 and MAPK activation and suppressing fibroblast activation.
s-Klotho suppresses Wnt signaling, reducing fibrosis and cellular senescence. KP6 specifically targets this pathway in diabetic kidney disease models.
Klotho attenuates insulin/IGF-1 pathways — relevant for metabolic health and longevity signaling; may influence how other metabolic peptides interact with these axes.
Klotho dampens NF-κB signaling, reducing TNF-α, IL-6, and other pro-inflammatory cytokines; complements anti-inflammatory peptides in preclinical contexts.
Secreted Klotho modulates renal and vascular ion channels, impacting calcium and potassium homeostasis independently of FGF23.
Reported Research Timeline
01Biweekly protocol — weeks 1–4 (baseline and early effects): At 10 mcg every two weeks, the primary goal of the first cycle is establishing a biomarker baseline and tolerability. Serum Klotho levels, eGFR, FGF23, inflammatory markers (IL-6, TNF-α), and any relevant cognitive or cardiovascular measures should be taken before the first injection. Subjective effects in this early phase are typically not pronounced.
02Biweekly protocol — months 2–3 (measurable shifts): With continued biweekly dosing, researchers tracking objective markers may begin to see changes in FGF23 signaling, phosphate handling, and inflammatory cytokine profiles by weeks 6–10. Cognitive and cardiovascular biomarker changes, if they occur, tend to emerge over this same window in the animal research literature that informs these human protocols.
03Intensive protocol (2–3× per week, weeks 1–12): The higher-frequency model is designed to achieve more robust receptor saturation and measurable biomarker shifts over a 12-week window. Outcomes tracked in this protocol include eGFR trajectory, serum Klotho levels (if measurable), and markers of oxidative stress and vascular endothelial function. At week 12, a 4-week break is mandatory before restarting.
04Long-term / repeat cycles (reported in cited studies): Klotho levels decline with age — the working hypothesis behind repeat dosing is that periodic restoration of circulating Klotho activity slows age-associated decline across the kidney, cardiovascular, and neurological systems. Human outcome data is limited; researchers are advised to track objective biomarkers across cycles rather than relying on subjective response as a guide. Adjust frequency and dosing based on measured results.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
No human safety data for exogenous Klotho or KP1 — translational safety is entirely untested in humans; all risk extrapolations are from mouse models only.
Prolonged TGF-β inhibition — TGF-β also plays immunoregulatory and tumor-suppressor roles; sustained blockade carries theoretical risks of immune dysregulation, impaired wound healing, or altered tumor biology.
KP1 tolerability in mice — well tolerated at 1 mg/kg/day IV with improved kidney function and fibrosis markers; no overt toxicity reported in published studies.
Klotho as a biomarker — clinical studies measuring Klotho are observational; no interventional human data exist for exogenous supplementation.
Supraphysiological Klotho risk — exceeding physiological Klotho ranges can paradoxically promote vascular calcification (reversing its protective effect), cause excessive phosphate excretion (hypophosphatemia), deplete potassium (hypokalemia), and generate surplus nitric oxide leading to oxidative stress and endothelial damage. Even a dosing error that approaches milligram amounts could overwhelm the system; the physiological range (~600–950 pg/mL) should be treated as a ceiling, not a floor. Electrolyte monitoring during any research protocol is advisable.
Do Not Use If:
Active or suspected malignancy (TGF-β pathway modulation carries unknown oncological implications)
Active autoimmune disease or immunosuppressive therapy (immune effects of TGF-β blockade are uncharacterized in humans)
Outside a supervised, institutional research protocol
Seek Medical Attention If:
Any immune or inflammatory reactions following administration
Unexpected neurological symptoms (severe headache, vision changes, confusion)
Persistent injection site reactions (redness, pain, or swelling beyond 48 hours)
Always consult a licensed physician before and during use
Quality Indicators
Verified
Sequence verification
Sequence verified against published human Klotho fragment (e.g., residues 56–87 for KP1).
Verified
HPLC purity & MS identity
Purity ≥98% confirmed by HPLC; identity confirmed by mass spectrometry (MS). CoA with batch number and test date.
Verified
Lyophilized powder appearance
White to off-white lyophilized powder; clear, colorless solution upon reconstitution in sterile aqueous solution.
Caution
Storage & stability
Store at –20 °C or below; protect from light and moisture. Reconstituted solution stable ≤30 days refrigerated (2–8 °C). Lyophilized powder stable 12–24 months at –20 °C.
CAUTION — NOT RECOMMENDED
Pre-mixed solutions
Pre-mixed solutions with unknown storage history or no reconstitution date. Vendor unable to provide sequence verification or CoA for a Klotho-derived peptide product.
Research Citations
- A Klotho-derived peptide protects against kidney fibrosis by targeting TGF-β signaling
Yuan Q, Ren Q, Li L et al., 2022, Nat Commun
- Klotho-derived peptide 6 ameliorates diabetic kidney disease by targeting Wnt/β-catenin signaling
Chen X, Tan H, Xu J et al., 2022, Kidney Int
- Klotho-derived peptide 1 inhibits cellular senescence in the fibrotic kidney by restoring Klotho expression via posttranscriptional regulation
Zhang X, Li L, Tan H et al., 2024, Theranostics
- Regulation of FGF23 production and phosphate metabolism by bone-kidney interactions
Agoro R, White KE, 2023, Nat Rev Nephrol
- Suppression of aging in mice by the hormone Klotho
Kurosu H, Yamamoto M, Clark JD et al., 2005, Science
"
Research Focus
Anti-Aging, Renal Fibrosis, CKD, Cardiovascular, Neuroprotection, TGF-β Inhibition
Verified Vendors Carrying Klotho
Frequently Asked Questions
What should researchers watch for with Klotho?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Klotho?
Biweekly protocol — weeks 1–4 (baseline and early effects): At 10 mcg every two weeks, the primary goal of the first cycle is establishing a biomarker baseline and tolerability. Serum Klotho levels, eGFR, FGF23, inflammatory markers (IL-6, TNF-α), and any relevant cognitive or cardiovascular measures should be taken before the first injection. Subjective effects in this early phase are typically not pronounced.
How is Klotho typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →